Mapping cell-to-cell communication to unlock new drug targets for CNS diseases, Violet Therapeutics has raised $4.8M in seed capital.
The pre-clinical stage company, co-founded in 2021 by Mass General Brigham Ventures and scientists from Brigham & Women’s Hospital, is leveraging its first-in-class platforms to identify, map, and mine cell-to-cell communication at scale for its drug discovery programs focused on central nervous system diseases.














